Published in JAMA Neurol on August 01, 2013
Distal Symmetric Polyneuropathy: A Review. JAMA (2015) 2.10
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis (2014) 1.58
Genetics of Charcot-Marie-Tooth (CMT) Disease within the Frame of the Human Genome Project Success. Genes (Basel) (2014) 1.56
CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry (2014) 1.11
MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol (2015) 0.98
Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis. J Peripher Nerv Syst (2014) 0.94
Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases. Neurology (2014) 0.90
Collaboration for rare disease drug discovery research. F1000Res (2014) 0.89
Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp Neurol (2014) 0.89
Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy. F1000Res (2014) 0.86
Overexpression of mutant HSP27 causes axonal neuropathy in mice. J Biomed Sci (2015) 0.81
Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease. ACS Chem Biol (2014) 0.80
Haplotype-specific modulation of a SOX10/CREB response element at the Charcot-Marie-Tooth disease type 4C locus SH3TC2. Hum Mol Genet (2014) 0.80
Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective. Neuromuscul Disord (2014) 0.80
The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management. Appl Clin Genet (2015) 0.78
A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orphanet J Rare Dis (2015) 0.77
Whither hope for pharmacological treatment of Charcot-Marie-Tooth disease type 1A? JAMA Neurol (2013) 0.76
The futility study-Progress over the last decade. Contemp Clin Trials (2015) 0.75
Promoting peripheral myelin repair. Exp Neurol (2016) 0.75
Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach. J Multidiscip Healthc (2016) 0.75
Transcriptome Analysis of Ullrich Congenital Muscular Dystrophy Fibroblasts Reveals a Disease Extracellular Matrix Signature and Key Molecular Regulators. PLoS One (2015) 0.75
A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients. PLoS One (2017) 0.75
Caveats in the Established Understanding of CMT1A. Ann Clin Transl Neurol (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell (1991) 7.93
Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet (1974) 5.80
Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol (2011) 4.37
Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44
Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord (1991) 3.37
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology (2006) 3.01
Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol (2009) 2.88
Analyzing incomplete longitudinal clinical trial data. Biostatistics (2004) 2.82
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol (2011) 2.44
Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology (1995) 2.42
Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet (1996) 2.40
Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care (2007) 2.29
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler (2008) 2.28
Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2009) 2.25
The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication. Nat Genet (1992) 2.18
Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst (2011) 2.03
Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med (2004) 1.86
CMT1X phenotypes represent loss of GJB1 gene function. Neurology (2007) 1.77
Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology (2008) 1.70
The phenotypic manifestations of chromosome 17p11.2 duplication. Brain (1997) 1.63
Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain (2005) 1.42
Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol (2012) 1.25
The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain (2009) 1.25
168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord (2010) 1.23
Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med (2009) 1.12
136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord (2006) 1.05
Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care (2007) 1.03
A futility study of minocycline in Huntington's disease. Mov Disord (2010) 0.94
PMP22 expression in dermal nerve myelin from patients with CMT1A. Brain (2009) 0.91
Vitamin C and human health--a review of recent data relevant to human requirements. Int J Vitam Nutr Res (1996) 0.91
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain (2005) 11.80
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Deliberations about deliberative methods: issues in the design and evaluation of public participation processes. Soc Sci Med (2003) 6.00
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 5.46
Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA (2012) 5.40
Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med (2004) 4.87
Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol (2011) 4.37
Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol (2004) 4.30
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain (2003) 4.24
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature (2007) 3.91
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
Differences between human and mouse embryonic stem cells. Dev Biol (2004) 3.30
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol (2005) 3.07
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol (2003) 2.81
MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain (2006) 2.77
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain (2013) 2.58
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain (2009) 2.49
Human herpesvirus (HHV)-6 and HHV-7 infections in pregnant women. J Infect Dis (2007) 2.29
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler (2008) 2.28
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain (2006) 2.23
An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord (2007) 2.17
Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family. Ann Neurol (2011) 2.09
Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst (2011) 2.03
The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve (2014) 2.02
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med (2009) 1.96
High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol (2011) 1.95
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain (2012) 1.88
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain (2010) 1.84
Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol (2010) 1.81
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Clinical profile and early surgical complications in the Cornea Donor Study. Cornea (2006) 1.77
The effect of the alignment of electrospun fibrous scaffolds on Schwann cell maturation. Biomaterials (2007) 1.72
Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol (2003) 1.72
Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. Brain (2009) 1.70
Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy. Am J Hum Genet (2010) 1.70
Recovery from paralysis in adult rats using embryonic stem cells. Ann Neurol (2006) 1.69
Update on Charcot-Marie-Tooth disease. Curr Neurol Neurosci Rep (2011) 1.66
Pain associated with multiple sclerosis: systematic review and proposed classification. Pain (2007) 1.65
HIV-associated sensory neuropathies. AIDS (2002) 1.65
A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol (2011) 1.64
Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms. Eur Urol (2006) 1.63
Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am J Transplant (2005) 1.63
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the name. Neurology (2002) 1.57
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56
Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain (2008) 1.55
Cognitive fatigue during a test requiring sustained attention: a pilot study. Mult Scler (2003) 1.53
Primary lateral sclerosis. Muscle Nerve (2007) 1.52
Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia. Am J Hum Genet (2013) 1.51
Genetic testing practices for Charcot-Marie-Tooth type 1A disease. Muscle Nerve (2013) 1.49
Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). J Pediatr (2004) 1.49
Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol (2006) 1.49
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neurosci (2008) 1.45
Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics (2008) 1.44
Acute inflammatory demyelinating polyneuropathy: contribution of a dispersed distal compound muscle action potential to electrodiagnosis. Muscle Nerve (2006) 1.44
Aligned Protein-Polymer Composite Fibers Enhance Nerve Regeneration: A Potential Tissue-Engineering Platform. Adv Funct Mater (2007) 1.43
Growth Hormone Therapy Accelerates Axonal Regeneration, Promotes Motor Reinnervation, and Reduces Muscle Atrophy following Peripheral Nerve Injury. Plast Reconstr Surg (2016) 1.43
Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J Neurosci (2005) 1.43
Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (cmtx5). Am J Hum Genet (2007) 1.42
Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther (2011) 1.42
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain (2005) 1.42
Epidermal nerve fibers: confidence intervals and continuous measures with nerve conduction. Neurology (2012) 1.41
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA (2012) 1.40
The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol (2014) 1.40
Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol (2003) 1.39
Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system. Pain (2016) 1.39
Effects of nebulized bronchodilator therapy on heart rate and arrhythmias in critically ill adult patients. Chest (2011) 1.39
Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr (2004) 1.37
Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies. Muscle Nerve (2004) 1.32
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol (2011) 1.32
Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology (2012) 1.31
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol (2009) 1.31
Axonal protective effects of the myelin-associated glycoprotein. J Neurosci (2009) 1.29
Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol (2002) 1.29
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol (2004) 1.28
Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry (2008) 1.27
Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol (2012) 1.25
The policy analysis of 'values talk': lessons from Canadian health reform. Health Policy (2004) 1.23
The Ste20 kinases Ste20-related proline-alanine-rich kinase and oxidative-stress response 1 regulate NKCC1 function in sensory neurons. J Biol Chem (2009) 1.23
Direct estimation of the area under the receiver operating characteristic curve in the presence of verification bias. Stat Med (2009) 1.23
Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther (2002) 1.22
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
Characterization of ganglionic acetylcholine receptor autoantibodies. J Neuroimmunol (2008) 1.21